New research reveals significant gaps between public perception and scientific evidence for medical cannabis benefits across most health conditions.

A recent review published in JAMA found that the evidence to support the use of cannabis and cannabinoids for most medical indications is insufficient. The authors state that only specific pharmaceutical-grade cannabinoid products approved by the Food and Drug Administration (FDA) have demonstrated clear clinical benefits.

Trump signed an EO to reschedule cannabis, lifting 280E taxes for US MSOs like Cresco Labs, as shares fell on profit taking. Read why CRLBF stock is a hold.

President Donald Trump on Thursday ordered federal agencies to quickly ease restrictions on marijuana and make CBD more available, the latest indicator of how the once-taboo drugs have increasingly become part of America’s mainstream.

The move wouldn't legalize marijuana, but moving it from Schedule I to Schedule III would allow the FDA to study it for medical purposes.

The review also found that daily use of medical cannabis — especially inhaled or high-potency products — may increase the risk of cardiovascular problems compared with occasional use. That includes a higher chance of heart attack, stroke and coronary artery disease.

President Trump signed an executive order reclassifying the federal status of marijuana, categorizing it as a drug with less potential for harm and dependence. It's a major shift in policy that could have wide-ranging effects on cannabis use and research.

The shift directed by President Trump — and President Biden before him — could also open the door to more research on the medical benefits of cannabis. But some observers also worry that implementation will come with significant challenges.